UroGen Pharma

Aging Demographics And Advanced Therapies Will Reshape Urology Practice

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

28 Aug 25

AnalystHighTarget's Fair Value

US$41.00

54.0% undervalued

05 Sep

US$18.88

41.4%

-2.9%

41.4%

-2.9%

Edit anytime before Aug 28 9:17 PM. Then post Updates to your followers.

Author's Valuation

US$41.0

54.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$41.0

54.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

38.92%

Biotech revenue growth rate

7.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.92%

Calculation

US$557.68m

Earnings '28

5.47x

PE Ratio '28

US$3.05b

Market Cap '28

US$3.05b

Market Cap '28

60.96m

No. shares '28

US$50.04

Share Price '28

US$50.04 Share Price '28

Discounted to 2025 @ 6.87% p.a.

US$41.00

Fair Value '25